Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments, and Hematopoietic Stem Cell Transplantation.
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study
Gilteritinib with or without venetoclax for relapsed/refractory <i>FLT3</i>‐mutated acute myeloid leukaemia
Post‐Relapse Outcomes of Older Patients With <i>NPM1</i>‐Mutated <scp>AML</scp> Are Favorable With Allo Transplant in Second Remission
Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
The Effect of Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes: A Study by the Israeli MDS Working Group
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis
Use of <scp>CYP3Ai</scp> and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the <scp>VIALE‐A</scp> study
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
Implementation of data protection laws in the European Union and in California is associated with a move of clinical trials to countries with fewer data protections
A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1).
Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression
The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice
Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples
Spontaneous arising of a lymphoblastoid B‐cell line harbouring a pre‐leukemic DNMT3A mutation in acute myeloid leukaemia cell culture
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study
Venetoclax is safe and efficacious in relapsed/refractory AML
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission
Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study
Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)—ViLen-01 protocol